|
|
| This month: The first-in-class JAK1/JAK2 inhibitor ruxolitinib phosphate, a treatment for patients with myelofibrosis
|
 |
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acute Radiation Syndrome Disease Briefing
now freely available in pdf format
| |
|
|
|
|
  DailyDrugNews.com is now
Thomson Reuters Drug News
Get the same Drug R&D News you expect, enhanced navigation and integration
Find out more |
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Functions of Vitamin D
An animation depicting the metabolism and functions of vitamin D. | |
|
|
|
|
 International Society Cardiovascular Pharmacotherapy
The ISCP is a society devoted to education and medical research in the field of cardiovascular pharmacotherapy, as well as to the international exchange of information and to the needs of cardiovascular pharmacotherapy with special focus on developing countries. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Drugs of the Future
Non-structural protein 5A (NS5A) is a promiscuous phosphoprotein essential to HCV genome replication, although the exact role it plays during the viral life cycle remains undefined. Small molecules targeting NS5A have proven to be potent inhibitors of HCV replication in vitro and in vivo, and some of them are now entering clinical development.
|
|
|
Drugs of Today
Azilsartan medoxomil is a novel prodrug that acts as a highly selective angiotensin II receptor blocker with potent blood pressure-lowering activity and a favorable safety profile when administered as a once-daily oral therapy either as a single agent or in combination with chlorthalidone or amlodipine in patients with hypertension.
|
|
|
|
